When was BMRT founded?

BMRT was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is BMRT located?

BMRT is headquartered in Palm City, United States.

Who is the current CEO of BMRT?

Bo Short of BMRT. They have also founded 1 company.

How many employees does BMRT have?

As of Mar 31, 2026, the latest employee count at BMRT is 6.

Is BMRT a funded company?

BMRT is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Nov 17, 2023.

When was the latest funding round of BMRT?

BMRT's latest funding was a $***** Series A round on Nov 17, 2023, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.73B in funding in 2026 to date.

Where does BMRT rank among its competitors?

BMRT ranks 15th amongst 103 active competitors, of which 34 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Lucida Medical, which secured $11.5M in Mar, 2026.

Who are the top competitors of BMRT?

BMRT's top competitors include Scholar Rock, Nanovery and SamanTree Medical. Among them, Lucida Medical secured the most recent funding round in March, 2026.

BMRT - 2026 Company Profile, Team, Funding & Competitors

BMRT is a series A company based in Palm City (United States), founded in 2023 by Lee Duke and Bo Short. It operates as a Provider of devices for diagnosis of cancer. BMRT has raised $3.06M in funding. The company has 103 active competitors, including 34 funded and 9 that have exited. Its top competitors include companies like Scholar Rock, Nanovery and SamanTree Medical.

Company Details

Provider of devices for diagnosis of cancer. The company's device detect any element, molecule, or substance based on its molecular structure, as well as detecting cancer on both lab slides and in human subject.

Website: bmrt.io
Email ID: *****@bmrt.io
Phone Number: +1 **********

Key Metrics

Founded Year

2023

Location

Palm City, United States

Stage

Series A

Total Funding

$3.06M in 1 round

Latest Funding Round

Series A, Nov 17, 2023, $*****

Ranked

15^th among 103 active competitors

Employee Count

6 as on Mar 31, 2026

Similar Companies

Nanovery & 103 more

View BMRT's full profile

BMRT has raised a total funding of $3.06M over 1 round.

Here is the list of recent funding rounds of BMRT:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 17, 2023	5134971	Series A	9321078	7504626	7968490	1442539

Access funding benchmarks and valuations. Sign up today!

View details of BMRT's funding rounds and investors

The founders of BMRT are Lee Duke and Bo Short. Bo Short is the CEO of BMRT.

Here are the details of BMRT's key team members:

Lee Duke: Co-Founder of BMRT.
Contact Info: 1 email address
Bo Short: Co-Founder & CEO of BMRT.
Contact Info: 1 email address

View details of BMRT's Founder profiles and Board Members

BMRT's employee count trend

BMRT has 6 employees as of Mar 26. Here is BMRT's employee count trend over the years:

Uncover BMRT's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BMRT include Scholar Rock, Nanovery and SamanTree Medical. Here is the list of Top 10 competitors of BMRT, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 9 others	61/100
2nd	Nanovery 2018, London (United Kingdom), Seed	Developer of nanobots for diagnosing cancer	$7.32M	prostate-cancer-research.org.uk, Earlymarket ... & 10 others	60/100
3rd	SamanTree Medical 2014, Lausanne (Switzerland), Series C	Developer of digital microscopy system for high-resolution imaging of tissue	$57.5M	Panakes Partners, European Investment Bank ... & 12 others	58/100
4th	Lucida Medical 2019, Cambridge (United Kingdom), Series A	Developer of MRI-based cancer screening technology using artificial intelligence (AI)	$11.5M	prostate-cancer-research.org.uk, IW Capital ... & 19 others	58/100
5th	Ionpath 2014, Menlo Park (United States), Series B	Developer of an imaging platform for tissue biopsies	$18M	Samsara BioCapital, Agile Angel & 8 others	53/100
6th	RAYDIAX 2021, Magdeburg (Germany), Series A	Developer of therapy-assist CT system for minimally invasive interventions	$8.4M	Bmp Ventures, HTGF & 4 others	52/100
7th	Adiposs 2018, Geneva (Switzerland), Series A	Developer of medical imaging equipment for the diagnosis of cachexia	$7.25M	Foundation Eclosion, Privilege Ventures & 7 others	51/100
8th	Windtree Therapeutics 1992, Philadelphia (United States), Public	Developer of therapies for oncology and cardiovascular diseases with unmet needs	$45K	VMS Asset Management, HHS & 2 others	51/100
9th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	51/100
10th	Ferronova 2016, Salisbury (Australia), Series A	Provider of magnetic probe based device of treatment of multiple cancer	$17.5M	Uniseed, SAVCF & 6 others	50/100
15th	BMRT 2023, Palm City (United States), Series A	Provider of devices for diagnosis of cancer	$3.06M	-	46/100